Arizona study to explore ibogaine for PTSD, brain injuries

Arizona researchers to study ibogaine for PTSD and brain injuries

Barrow Neurological Institute is set to begin enrolling patients next year for a study investigating the safety and efficacy of ibogaine in treating neurological disorders, including traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD). The research is supported by a $5 million grant from the state of Arizona, according to KJZZ.

Study details and methodology

Dr. Susan Criswell, chief medical officer for clinical research at Barrow Neurological Institute, explained that the study will be a Phase I/II double-blind, placebo-controlled trial. The trial will involve 40 adults with chronic TBI symptoms, with half receiving a single dose of ibogaine and the other half a placebo. Participants will be monitored over six months to assess any persistent improvements in symptoms. The study will be conducted in collaboration with Arizona State University.

Safety and potential mechanisms

Safety is a primary concern for the researchers, as ibogaine has not been previously administered in the U.S. The trial will take place in an intensive care unit with rigorous monitoring, including cardiac checks and vital sign assessments. Dr. Criswell mentioned that the study will also explore ibogaine's potential as a neuroplastogen, a substance that could promote neuroplasticity, which might be beneficial for individuals with TBI.

Timeline and regulatory hurdles

The study is expected to span five years, with patient enrollment anticipated to start in about a year. The initial phase will focus on regulatory approvals and contracting, given that ibogaine is a novel substance in the U.S. The final year will concentrate on analyzing and publishing the results.

Why it matters

This study could provide critical insights into ibogaine's potential as a treatment for PTSD and brain injuries, conditions that significantly impact quality of life. If successful, it may pave the way for new therapeutic approaches for neurological disorders.

Dr. Susan Criswell emphasized the importance of rigorous scientific methods in this trial, which aims to build on anecdotal evidence and early studies that suggest ibogaine may help reorganize brain connections.

The research is part of a broader interest in psychedelics as potential treatments for mental health and neurological conditions, driven by increasing public and scientific curiosity.